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Abstract 
Undifferentiated nasopharyngeal carcinoma (NPC) is a cancer with high metastatic potential that is 
consistently associated with Epstein-Barr virus (EBV) infection. In this study, we have investigated 
the functional contribution of sphingosine-1-phosphate (S1P) signalling to the pathogenesis of 
NPC. We show that EBV infection or ectopic expression of the EBV-encoded latent genes 
(EBNA1, LMP1 and LMP2A) can up-regulate sphingosine kinase 1 (SPHK1), the key enzyme that 
produces S1P, in NPC cell lines. Exogenous addition of S1P promotes the migration of NPC cells 
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through the activation of AKT; shRNA knockdown of SPHK1 resulted in a reduction in the levels 
of activated AKT and inhibition of cell migration. We also show that S1P receptor 3 (S1PR3) 
mRNA is over-expressed in EBV-positive NPC patient-derived xenografts and a subset of primary 
NPC tissues, and that knockdown of S1PR3 suppressed the activation of AKT and the S1P-induced 
migration of NPC cells. Taken together, our data point to a central role for EBV in mediating the 
oncogenic effects of S1P in NPC and identify S1P signalling as a potential therapeutic target in this 
disease. 
 
Keywords: Nasopharyngeal carcinoma, Epstein-Barr virus, Sphingosine-1-phosphate, S1P receptor 
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Introduction 
Nasopharyngeal carcinoma (NPC) is a highly metastatic cancer that is exceptionally prevalent in 
Southern China and South East Asia [1, 2]. Approximately 75% of NPC patients present with late 
stage disease and approximately 30% of these patients develop distant metastases post therapy [1, 
3]. Existing treatment for advanced disease is limited to concurrent chemoradiotherapy and 
unfortunately, due to the location of tumours in close proximity to vital organs in the head and neck 
region, most survivors of NPC have an impaired health-related quality of life [4, 5]. A deeper 
understanding of the molecular basis of NPC is required to inform innovations in the therapeutic 
approach.  
 
Undifferentiated NPC is invariably associated with Epstein-Barr virus (EBV) infection [6]. 
EBV latent gene expression in NPC is restricted to Epstein-Barr nuclear antigen 1 (EBNA1), latent 
membrane proteins (LMP 1 and LMP2), EBV-encoded RNAs (EBERs) and BamHI-A transcripts. 
Although the exact pathogenic role of EBV in NPC tumorigenesis remains to be fully elucidated, it 
is well established that the expression of these EBV latent genes results in the perturbation of many 
cellular processes, which leads to the development of NPC.  
 
Given that distant metastasis is a major cause of death for NPC patients, we focused on the 
possibility that sphingosine-1-phosphate (S1P) signalling, a pathway that has been shown to 
promote cancer cell migration and invasion [7], could be involved in the pathogenesis of NPC. S1P 
is a bioactive lipid mainly produced by sphingosine kinase 1 (SPHK1) [8], an enzyme that is 
activated following phosphorylation at Ser225 by extracellular signal-regulated kinase 1/2 (ERK 
1/2) and translocated to the plasma membrane to generate S1P [9].  High expression of SPHK1 was 
shown to be associated with poor prognosis in NPC [10], but the downstream biological 
consequences of elevated SPHK1 in NPC cells have not been studied. The pro-oncogenic effects of 
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S1P have been suggested to be mainly a consequence of alterations in the expression or function of 
one or more of five known G protein-coupled receptors (GPCR), S1PR1-5 [11]. We were 
particularly interested to explore if the aberrant activation of the SPHK1/S1P/S1PR axis could 
contribute to the migratory potential of NPC. We show for the first time that EBV infection 
enhances the expression of SPHK1 in NPC cells, and S1P induces migration of NPC cells by 
activating AKT through S1PR3. 
 
Materials and Methods 
Cell lines, xenografts and tissue samples 
The cell lines used in this study included: an immortalised nasopharyngeal epithelial cell line, 
NP69; eight NPC-derived cell lines, of which seven are EBV-negative (CNE1, CNE2, HK1, 
HONE1, SUNE1, TW01, TW04) and one of which is EBV-positive (C666-1). NPC cells stably 
infected with a recombinant EBV (Akata strain) or expressing individual EBV-encoded latent genes 
were generated, as previously described [12]. Four NPC patient-derived EBV-positive xenografts 
(xeno-2117, xeno-666, C15 and C17) were used in this study [13-15]. Paraffin-embedded archival 
NPC and non-malignant nasopharyngeal tissue samples were obtained from the tissue bank of 
Department of Anatomical and Cellular Pathology at the Prince of Wales Hospital, The Chinese 
University of Hong Kong (CUHK). The study protocol was approved by the Clinical Research 
Ethics Committee of the CUHK.  All NPC samples were non-keratinising EBER-positive. The 
study protocol was approved by the Joint Chinese University of Hong Kong – New Territories East 
Cluster Clinical Research Ethics Committee, Hong Kong. The clinical characteristics of the NPC 
samples are listed in Supplementary Table S1. 
 
 
Reverse Transcription - Quantitative PCR (RT-qPCR) 
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Total RNA was extracted using a RNeasy Mini Kit (Qiagen, UK) and subjected to reverse 
transcription using High-Capacity cDNA Reverse Transcription kit (Applied Biosystems, USA). 
Quantitative PCR was performed in triplicate using the ABI Prism 7000 Sequence Detection 
System and TaqMan Gene Expression Assays (SPHK1: Hs00184211_m1; S1PR3: Hs00245464_s1; 
Applied Biosystems, USA). GAPDH was amplified in the same reaction to serve as an internal 
control for normalization. Fold changes in gene expression were measured using the comparative 
threshold cycle method (ΔΔCt). 
 
Western blotting  
 
Cells were lysed in ice-cold NP40 lysis buffer [150 mM NaCl, 1% IGEPAL® CA-630, 50 mM 
Tris-HCl (pH 8.0)] containing protease inhibitors (cocktail set III; Calbiochem, Merck Millipore) 
and phosphatase inhibitors (Halt phosphatase inhibitor cocktail; Thermo Scientific, USA).  Samples 
containing equal amounts of protein were separated under reducing conditions using SDS-PAGE 
and the proteins transferred to polyvinylidene difluoride membranes (Millipore, UK).  The primary 
antibodies used in this study were anti-phospho-SPHK1 (Ser-225; SP1641; dilution 1:1000; ECM 
Biosciences, USA), anti-total SPHK1 (3297; dilution 1:1000; Cell Signaling Technology, USA), 
anti-phospho-AKT (Ser473; 9271; dilution 1:1000; Cell Signaling Technology, USA), anti-total 
AKT (9272; dilution 1:1000; Cell Signaling Technology, USA), anti-α-tubulin (T9026; dilution 
1:10000; Sigma-Aldrich, USA) and anti-β-actin (A5441; dilution 1:5000; Sigma-Aldrich, USA).  
Bound antibodies were detected with peroxidase conjugated secondary antibodies and Enhanced 
Chemiluminescence reagents (Advansta, USA).   
 
Transwell migration and invasion assays 
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Migration assays were carried out using fibronectin-coated (10 µg/ml) polycarbonate filters (8 µm 
pore size, Transwell, Corning). Cells were incubated in RPMI/0.5% FBS overnight and re-
suspended in migration buffer [RPMI containing 0.25 mg/ml fatty acid-free human albumin 
(Sigma)]. 1 x 106 cells were plated into the upper chamber and allowed to migrate for 19 h in the 
presence or absence of S1P (Enzo Life Sciences) in the lower chamber. Migrated cells were stained 
with 0.1% crystal violet and counted in five random fields. For experiments using inhibitors of 
AKT (LY294002; 1 μM; Merck, Germany) and S1PR1/S1PR3 (VPC23019; 1 μM; Tocris 
Bioscience, USA), the inhibitors were added to the both lower and upper chambers and S1P (5 μM) 
added to the lower chamber. For invasion assays, pre-coated invasion chambers (8 µm pore size, 
BD BioCoat Matrigel) were used and cells allowed to invade for 48 h. 
 
Knockdown of SPHK1, AKT and S1PR3 
Two SPHK1 shRNA lentiviral plasmids (pLKO.1/shSPHK1_S1, pLKO.1/shSPHK1_S2) and the 
non-targeting (control) shRNA (pLKO.1/NS) were kindly provided by Prof Chee-Onn Leong 
(International Medical University, Malaysia). Briefly, 293T cells were transfected with the lentiviral 
construct using polyethylenimine together with the packaging plasmid (psPAX2) and envelope 
plasmid (pMDG2). At 48 h post-transfection, the lentivirus-containing supernatant was centrifuged 
and filtered through a 0.45 µm syringe filter. The viral supernatants and polybrene (8 µg/ml) were 
then added to plates cultured with NPC cells and incubated for 16 h. The virus-containing media 
were then removed and the cells cultured in RPMI/10% FBS for an additional 48 h before selecting 
the transfected cells with 0.5-1 μg/ml puromycin. To knockdown AKT and S1PR3, pre-designed 
RNAi SMART pool reagents (AKT1: L-003000-00; S1PR3: LU-005208-00) were obtained from 
Dharmacon (Chicago, IL) and used at 25 nM. 5x104 cells per well were seeded into 6-well plates, 
cultured for 16 h and then transfected with the relevant siRNA using Oligofectamine (Invitrogen, 
UK).   
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Expression of constitutively active AKT 
The vector carrying a myristoylated form of AKT, 1036 pcDNA3 Myr HA Akt1 (Addgene plasmid 
# 9008) [16], was used to express constitutively active AKT. Cells at 50% confluency were 
transfected with the 1036 pcDNA3 Myr HA Akt1 or the empty vector at a 3:1 FuGENE HD 
transfection reagent (Promega, USA):DNA ratio. Cells were used in Transwell migration assays 24 
h post-transfection. 
 
RNA in situ hybridization  
SIPR3 mRNA expression in the NPC specimens was detected by RNAscope 2.0 assay with a 
SIPR3-specific probe (Advanced Cell Diagnostics, Hayward, CA, USA). FFPE tissue and cell block 
sections (5 μm) were deparaffinized in xylene and then dehydrated in a series of ethanol in water. 
The S1PR3-specific probes were hybridized to the sections, followed by incubation with 
preamplifier, amplifier and labelled probes.  
The chromogenic detection procedures were performed according to the manufacturer’s 
instructions. SIPR3 expression was assessed by assigning a proportion score and an intensity score. 
The proportion score relates to the percentage of tumour cells with brown signals (0-100). The 
intensity score represents the average abundance of signals in the tumour cells (0, none; 1, weak; 2, 
intermediate; 3, strong). The SIPR3 expression score was the product of the proportion and intensity 
scores, ranging from 0 to 300. 
 
Analysis of microarray data 
Microarray raw data, GSE12452 and GSE34573, were downloaded from GEO and re-analysed to 
identify genes differentially expressed between micro-dissected NPC tissues and normal 
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nasopharyngeal epithelium. Probe level quantile normalisation [17], RMA (robust multi-array 
analysis) [18] and MAS5 detection analyses were performed using the affy package of the 
Bioconductor project (http://www.bioconductor.org). P-values and fold-changes were calculated 
using limma [19]. Affymetrix “HG-Focus.na35.annot.csv” was used for probe set annotation. Probe 
sets with “Negative Strand Matching Probes” were removed. Differentially expressed genes were 
identified using the criteria of fold-change > 1.5 and p-value < 0.05. 
 
Statistical analyses 
All statistical analyses were performed using SPSS 23.0 for Windows (IBM Inc., USA) or 
GraphPad Prism Version 5 (GraphPad Software Inc., USA). For RT-qPCR and migration/invasion 
assays, statistical differences between experimental groups were evaluated by Student’s t-test or 
one-way analysis of variance (ANOVA)/Dunnett’s test. A receiver operating characteristic (ROC) 
curve was constructed using S1PR3 expression scores to select the best cut-off point (maximum 
sensitivity and specificity) that is relevant to the patient survival [20]. NPC cases were group into 
cases with low (score 0-45) or high (score 46-200) expression of S1PR3. Kaplan-Meier survival 
analysis was used to correlate survival rates with S1PR3 expression and the survival probability 
differences were compared by log-rank test. Values of p < 0.05 were regarded as significant. 
 
Results 
EBV infection of NPC cells increases the expression of SPHK1 
Given that SPHK1, the key enzyme that produces S1P, has been shown to be commonly expressed 
in primary NPC tissues [10], we opted to investigate whether EBV infection could modulate 
SPHK1 levels in NPC cells. We first compared SPHK1 mRNA expression in eight NPC cell lines 
with that in the immortalised nasopharyngeal epithelial cell line NP69. Among the three NPC cell 
lines that expressed significantly higher levels of SPHK1, we had noted that C666-1, the only EBV-
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positive NPC cell line, showed an exceptionally high expression of SPHK1 (Figure 1A). We 
subsequently found that SPHK1 mRNA abundance was significantly higher in six out of seven NPC 
cell lines stably infected with a recombinant EBV (Akata strain) (p<0.01; Figure 1B). After first 
validating the specificity of antibodies against total and phosphorylated SPHK1 proteins 
(Supplementary Figure S1), we showed that while the increased expression of the total SPHK1 
protein was confirmed in three representative EBV-infected NPC cell lines, the levels of 
phosphorylated SPHK1 protein were also increased in these cell lines (Figure 1C). Next, we 
investigated which EBV gene(s) were responsible for this effect. To do this, we examined SPHK1 
expression in HONE1 cells individually transfected with EBNA1, LMP1 or LMP2A, all of which 
are expressed in NPC in vivo. We found that both the mRNA and protein levels of SPHK1 were up-
regulated by all the three EBV latent genes in HONE1 cells, with the most marked effect in 
LMP2A-expressing cells (Figure 1D). We conclude that EBV infection can up-regulate the 
expression of SPHK1, hence high levels of S1P are likely to be present in EBV-positive NPC cells. 
 
S1P enhances the migration of NPC cells 
Next, we used Transwell assays to investigate the effects of S1P on the migration of NPC cells 
using three representative NPC cell lines (TW04, HONE1 and SUNE1). We found that the 
exogenous addition of S1P significantly increased the migration of all three cell lines (p<0.001; 
Figure 2A). Given that C666-1 cells do not migrate in Transwell assays, even in the presence of 
10% FBS or S1P, we performed wound healing assays using charcoal-stripped FBS. Similarly, S1P 
enhanced C666-1 cell migration (Supplementary Figure S2). S1P also promoted the invasion of 
SUNE1 cells (Supplementary Figure S3).  We next measured migration in HONE1 cells following 
their transduction with two different shRNAs targeting SPHK1 (shSPHK1_S1 or shSPHK1_S2), or 
with a non-targeting shRNA (NS), as a control. Reduced expression of both SPHK1 mRNA and 
protein in transfected HONE1 was confirmed by RT-qPCR and western blot analyses, respectively 
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(Figure 2B). In line with the data that S1P induced NPC cell migration, knockdown of SPHK1 
expression suppressed the migration of HONE1 cells (p<0.001; Figure 2C).   
 
S1P induces NPC cell migration through activation of AKT 
We next investigated the mechanism of S1P-induced migration of NPC cells. We focussed on the 
AKT pathway because AKT has been shown to be a central player in mediating the oncogenic 
effects of S1P and its activation promotes cancer cell migration in various solid tumour types [7]. 
Secondly, activation of the PI3K/AKT pathway is a common feature of NPC and this pathway is 
stimulated by the EBV-encoded LMP1 or LMP2A to promote the migration and invasion of NPC 
cells [21]. We found that the addition of exogenous S1P activated AKT in both HONE1 and TW04 
cells (Figure 3A). To determine if the activation of AKT by S1P was responsible for the increased 
migration, we treated NPC cells with a PI3K/AKT inhibitor, LY294002. After first confirming the 
inhibitory effects of LY294002 on AKT phosphorylation (Supplementary Figure S4), we showed 
that treatment of HONE1 and SUNE1 with LY294002 led to a significant reduction in cell 
migration in the presence of S1P (p<0.001; Figure 3B). Similarly, knockdown of AKT with a pool 
of four siRNAs targeting AKT significantly suppressed the migration of both HONE1 and SUNE1 
cell lines (p<0.001; Figure 3C). In keeping with these observations, the knockdown of SPHK1 also 
resulted in a significant reduction in the levels of activated AKT in HONE1 cells (Figure 3D). 
Furthermore, the expression of a constitutively active AKT was able to rescue the repressive effects 
of SPHK1 knockdown on cell migration (p<0.001; Figure 3E). Taken together, our results show 
that S1P induces the migration of NPC cells through the activation of AKT. 
 
Over-expression of S1PR3 in NPC 
We next explored which S1P receptors might be responsible for mediating the S1P-induced 
migration of NPC cells. Re-analyses of two published microarray datasets, GSE12452 [22] and 
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GSE34573 [23], revealed significant and consistent up-regulation of S1PR3 mRNA expression in 
micro-dissected NPC cells compared to normal epithelium (p<0.05; Figure 4A). Expression of the 
other four S1P receptor genes was either not significantly different or not consistently altered in 
both datasets (Supplementary Table S2). We attempted to examine the expression and cellular 
localisation of S1PR3 protein in primary NPC tissues using immunohistochemistry, however, none 
of the three anti-S1PR3 antibodies tested were suitable. Therefore, we opted to use sensitive RNA 
in situ hybridization (RNAscope) to examine the expression of S1PR3 in C666-1 cells, four EBV-
positive NPC patient-derived xenografts (xeno-666, xeno-2117, C15 and C17), an independent 
cohort of 21 formalin-fixed paraffin-embedded primary NPCs and nine non-malignant 
nasopharyngeal samples. We showed that C666-1 cells, xeno-666 and C15 demonstrated strong 
staining for S1PR3, while weak expression was observed in xeno-2117 and C17 (Figure 4B). In 
tissue samples, normal surface epithelium and epithelium adjacent to the carcinoma were 
consistently negative, whereas S1PR3 expression was detected in 13 of 21 (62%) of the primary 
NPCs examined (Figure 4C).  
 
S1P mediates migration of NPC cell by activating AKT through S1PR3 
Having shown that S1PR3 is over-expressed in primary NPC, we next wanted to determine if this 
receptor was involved in the activation of AKT and increased migration of NPC cells. To do this, 
we first treated two NPC cell lines that express S1PR3 (HONE1 and SUNE1; Supplementary 
Figure S5) with a S1PR1/S1PR3 antagonist, VPC23019. We found that VPC23019 decreased the 
migration of both cell lines in the presence of S1P (p<0.001; Figure 5A). Next, we transfected 
SUNE1 cells with a pool of four siRNAs targeting S1PR3 and the reduced expression of S1PR3 was 
confirmed by RT-qPCR analysis (Figure 5B). We observed that knockdown of S1PR3 reduced the 
levels of activated AKT (Figure 5C) and partially suppressed the migration of SUNE1 cells in the 
presence of S1P (p<0.001; Figure 5D). To further confirm these effects, we co-transfected SUNE1 
cells with a constitutively active AKT and S1PR3 siRNAs. Expression of a constitutively active 
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AKT restored the migration of these cells (p<0.001; Figure 5E). We conclude that S1P enhances the 
migration of NPC cells via the activation of AKT by S1PR3.    
 
Discussion 
S1P signalling affects many processes involved in carcinogenesis and there is now a growing 
appreciation that the oncogenic effects of S1P are dependent on the enzymes that generate or 
degrade S1P, and/or alterations in the expression of S1P receptors [7, 11]. Thus, the 
SPHK/S1P/S1PRs axis has become an attractive therapeutic target in cancer. Two functional SPHK 
isoforms, SPHK1 and SPHK2, have been identified in humans [24]. Whilst the role of SPHK2 in 
carcinogenesis remains to be fully explored, the tumour-promoting role of SPHK1 is well 
acknowledged [25]. Indeed, over-expression of SPHK1 has been reported in various types of 
cancer, including NPC [10, 25]. A wide variety of stimuli, including growth factors, GPCR 
agonists, cytokines, phorbol esters, and vitamin D3, can increase SPHK1 levels [26]. In the present 
study, we have identified a novel role for EBV in stimulating the expression and activation of 
SPHK1 in NPC cell lines. Although the mechanisms by which the EBV-encoded genes up-regulate 
the transcription of SPHK1 are yet to be determined, LMP1 and LMP2A are known to activate the 
ERK-MAPK pathway in NPC [27] and this, in turn, would likely result in the phosphorylation of 
SPHK1.  
 
High level expression of SPHK1 increases the production of S1P and elevated levels of S1P 
promote a number of malignant phenotypes associated with cancer cells, including proliferation, 
migration, invasion and angiogenesis [7]. Focussing on the migratory phenotype, our data show 
convincingly that S1P promotes the migration of NPC cells through the activation of AKT, and 
these effects were reversed by the knockdown of SPHK1. We further show that S1P activates AKT 
specifically via S1PR3 to promote the migration of NPC cells. Significantly, the PI3K/AKT 
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signalling pathway is frequently activated in NPC [21]. There is large body of evidence to show that 
S1P-induced migration of cancer cells is dependent upon the expression pattern of S1P receptors 
[28]. S1PR1 and S1PR3 have been shown to stimulate cell migration by coupling to Gi to activate 
Rac through PI3K; although S1PR2 is generally thought to inhibit cell migration via G12/13, we 
recently showed that S1PR2 contributes to the S1P-induced migration of oral cancer cells [29]. The 
involvement of S1PR3-mediated AKT activation in S1P-induced migration has previously been 
inferred indirectly, in a limited number of studies. For example, S1P activated AKT in endothelial 
cells, ovarian cancer cells and thyroid cancer cells and treatment of these cells with LY294002 or 
wortmannin suppressed S1P-induced migration in a Gi-dependent manner [30-32]. Although these 
studies used the S1PR1/3 inhibitor, VPC23019, to reveal the possible involvement of S1PR1 and 
S1PR3 in mediating these effects, it was not clear which receptor was precisely responsible. Similar 
observations were reported in breast cancer cells, but here, S1P induced migration was mediated 
through Gαq [33]. Although knockdown of Gαq or S1PR3 inhibited AKT phosphorylation, the 
authors did not provide a direct role for S1PR3 in mediating the migration of breast cancer cells 
through AKT. Therefore, we are the first to demonstrate that S1PR3 stimulates cell migration via 
the activation of AKT. 
 
The pro-migratory feature of S1PR3 was also reported to be mediated through the 
accumulation of phosphorylated ERK1/2 into membrane ruffles/lamellipodia and the nucleus of the 
breast cancer cell line, MCF-7 [34]. In the present study, S1P induced the phosphorylation of ERK 
in NPC cells; however, knockdown of SPHK1 did not affect the levels of phosphorylated ERK 
(data not shown). Nonetheless, we cannot rule out the possibility that S1PR3 can also mediate the 
S1P-induced migration of NPC cells through mechanisms other than AKT activation. S1P/S1PR3 
signalling has been shown to promote cancer cell migration/invasion by up-regulating the 
expression of epidermal growth factor receptor (EGFR), hypoxia-induced factor-1 (HIF-1) or C-
reactive protein (CRP) [35-37]. The identification of effector(s) downstream of S1P/S1PR3/AKT 
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signalling that stimulate the migration of NPC cells warrants further investigation. Further, we 
noted that knockdown of S1PR3 did not completely suppress the S1P-induced migration in SUNE1 
cells. There are two possible reasons to explain these observations; one is the incomplete 
knockdown of S1PR3, and the second, another S1P receptor(s) might also be involved. Given that 
the up-regulation of S1PR5 was demonstrated in one of the microarray studies (Table S2), the 
involvement of this receptor in S1P-induced migration of NPC cells cannot be ruled out. Although 
the role of S1PR5 in tumorigenesis is still uncertain, it remains a possibility that by coupling to Gi, 
S1PR5 can trigger Rac that leads to an increase in NPC cell migration. 
 
It has been shown that SPHK1 and S1PR3 function in an amplification loop to promote the 
migration of breast cancer cells [34]. However, we did not observe any consistent changes in 
S1PR3 expression following either knockdown of SPHK1 or EBV infection of NPC cells (data not 
shown). Since C15 is the only NPC xenograft that expresses LMP1, the high level expression of 
S1PR3 in C15 prompted us to investigate whether LMP1 could modulate S1PR3 expression. 
However, of the 19 tumours in this series that were also stained for LMP1, we did not observe a 
correlation between S1PR3 and LMP1 expression (data not shown). Therefore, the mechanisms that 
regulate S1PR3 expression in NPCs remain to be determined and our data suggest that the 
expression of SPHK1 and S1PR3 in NPC cells are regulated by different mechanisms. Irrespective 
of these differences, high levels of SPHK1 in NPCs have been correlated with poor patient 
prognosis [10] and high level expression of S1PR3 in the present study is associated with a worse 
overall survival in NPC patients (p<0.05; Supplementary Figure S6), data that are in line with those 
of Watson and colleagues who reported an association between high S1PR3 expression and shorter 
disease-specific survival in breast cancer patients [38].  
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In summary, we report for the first time that S1P is likely produced by NPC cells through the 
up-regulation of SPHK1 following EBV infection, and that S1P contributes to a migratory 
phenotype of NPC cells by activating AKT through S1PR3. Our data highlight the potential of 
targeting of SPHK1/S1P/S1PR3 axis in NPC patients. 
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Editorial comments on figures 
 
Fig 1 ~17x15 cm @300 ppi RGB but could be greyscale. Some westerns have limited background detail- 
please replace. [Yap: the western images have now been replaced] 
Fig 2 ~17x13 cm @300 ppi RGB but could be greyscale. A. please use a space between values and units (1 
µM, etc) B, the western for Total SPHK1 has limited background detail- please replace.  The western for a-
tubulin has a vertical anomaly between the first and second lane – if lanes are shown in an altered order 
the join should be marked with a black or white line.  [Yap: a space is now included; western images have 
been replaced] 
Fig 3 ~17x19 cm @300 ppi RGB but could be greyscale.  Please use a space between values and units (15 
min, etc).  The westerns show almost no background detail – please replace.  [Yap: a space is now included; 
the western images have been replaced] 
Fig 4 ~14x20 cm @800 ppi RGB. Please remove parentheses around panel labels A, B, C. Please align labels 
above image panels. The red arrows used are too thin to be clearly visible in the print version.  [Yap: 
parentheses are now removed; labels are aligned; red arrows are thickened] 
Fig 5 ~17x13 cm @300 ppi RGB could be greyscale.  A, please align the two charts. C, D, E most western 
panels have almost no background detail – please replace. [Yap: the two charts are now aligned; western 
images have been replaced] 
Several Suppl Figures appear to be in CMYK mode – should be RGB or Greyscale as appropriate. All 
supplementary figures appear to be low resolution figures upscaled (blurry with poorly defined lettering). 
Suppl figures do not need to be made to the same standard as main figures but please improve if possible. 
[Yap: all figures are now exported as RGB] 
Fig S1 Please separate values from units:  37 kDa [Yap: a space is now included] 
Fig S2 OK 
Fig S3 Please separate values from units:  5 µM [Yap: a space is now included] 
Fig S4 western panels have almost no background detail – please replace. [Yap: the western images have 
been replaced] 
Fig S5 OK GAPDH and other mRNA should be in italic font [Yap: they are now in italic] 
Fig S6 OK 
 
 
 
Figure legends 
 
Figure 1. EBV infection up-regulates the expression of SPHK1. (A) Compared to an immortalised 
nasopharyngeal epithelial cell line (NP69), SPHK1 levels were significantly increased in three 
(C666-1, HONE1 and TW01) out of eight NPC cell lines examined. Among these, C666-1 
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SUPPLEMENTARY MATERIAL ONLINE 
 
Supplementary materials and methods  NO 
 
Supplementary figure legends  YES 
 
Figure S1 Validation of the specificity of antibodies against total or phosphorylated SPHK1 protein 
 
Figure S2 S1P promotes migration of C666-1 cells in wound healing assays 
 
Figure S3. S1P enhances invasion of SUNE1 cells in vitro 
 
Figure S4. Confirmation of the inhibition of AKT activation following treatment with a PI3K/AKT 
inhibitor, LY294002 
 
Figure S5. Expression profiles of S1P receptors in HONE1 and SUNE1 cells. All five receptor 
mRNAs were detected in both cell lines 
 
 
Figure S6. Kaplan Meier survival analysis revealed higher expression of S1PR3 correlated with 
poor patient survival (p<0.05) 
 
Table S1. Clinical characteristics of primary NPC samples 
 
Table S2. Summary of the mRNA expression of five S1P receptors in NPC cells 
 
 
This article is protected by copyright. All rights reserved.
